Extensive <sup>177</sup>Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy-like Picture.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35688660.
- Also identified by DOI 10.1016/j.eururo.2022.05.025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lutetium-177 prostate-specific membrane antigen (<sup>177</sup>Lu-PSMA) radioligand therapy is an option that is increasingly being used for treatment of metastatic castration-resistant prostate cancer. This delivers β-radiation to cells expressing PSMA and high accumulation of the radiopharmaceutical occurs in the kidneys. Here we report three cases of radiation nephropathy with severe chronic kidney disease induced by renal thrombotic microangiopathy following extensive treatment with <sup>177</sup>Lu-PSMA radioligand therapy.
Medical subject headings
- Prostatic Neoplasms, Castration-Resistant
- Thrombotic Microangiopathies